Following his presentation at ACR 2020, we spoke with Richard Furie (Northwell Health Zucker School of Medicine at Hofstra/Northwell, NY, USA) about the novel IL-2 conjugate, NKTR-358 in patients with systemic lupus erythematosus (Clinical Trial Identifier: NCT03556007). The abstract ‘Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358.’ (ABSTRACT NUMBER: 1824) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- Could you give us a brief overview of therapeutic advances in systemic lupus erythematosus (SLE) in recent years? (0:26)
- What unmet needs remain in the treatment of SLE? (1:54)
- What is NKTR-358 and what is the rationale for its use in SLE? (2:32)
- Could you tell us about the Phase 1b study of NKTR-358 and its findings? (5:25)
- What will be the next step in the clinical development of NKTR-358? (9:36)
Disclosure: Dr. Furie has received personal research consulting fees as well as research support from Nektar and Eli Lilly.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
